Showing results (201-210 of 605) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|February 27, 2021
Mixture Cure Models in Oncology: A Tutorial and Practical GuidanceFederico Felizzi, Noman Paracha, Johannes Pöhlmann, et al.
Pharmacoeconomics - Open|December 28, 2021
Cost Effectiveness of Digital Interventions for Generalised Anxiety Disorder: A Model-Based AnalysisDina Jankovic, Pedro Saramago Goncalves, Lina Gega, et al.
Pharmacoeconomics - Open|October 17, 2022
Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in AustraliaLouisa G Gordon, C Wood, R W Tothill, et al.
Pharmacoeconomics - Open|September 4, 2022
Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab VedotinHolly Cranmer, David Trueman, Elise Evers, et al.
Pharmacoeconomics - Open|September 14, 2022
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic SteatohepatitisMehdi Javanbakht, Jesse Fishman, Eoin Moloney, et al.
Pharmacoeconomics - Open|November 5, 2022
A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in CanadaAnuja Chatterjee, Gijs van de Wetering, Ron Goeree, et al.
Pharmacoeconomics - Open|September 19, 2022
Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in AustraliaKaran K Shah, Melina Willson, Blaise Agresta, et al.
Pharmacoeconomics - Open|August 29, 2022
Cost-Effectiveness Analysis of Olaparib in Combination with Bevacizumab Compared with Bevacizumab Monotherapy for the First-Line Maintenance Treatment of Homologous Recombination Deficiency-Positive Advanced Ovarian CancerDavid Elsea, Lin Fan, Adela Mihai, et al.
Pharmacoeconomics - Open|August 30, 2022
Cost-Effectiveness Analyses of Lung Cancer Screening Using Low-Dose Computed Tomography: A Systematic Review Assessing Strategy Comparison and Risk StratificationMatthew Fabbro, Kirah Hahn, Olivia Novaes, et al.
Pharmacoeconomics - Open|August 25, 2022
Cost-Utility of Nivolumab Plus Ipilimumab in First-Line Treatment of Advanced Melanoma in the United States: An Analysis Using Long-Term Overall Survival Data from Checkmate 067Timothy Baker, Helen Johnson, Srividya Kotapati, et al.
Pageof 61